Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial

During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

A fast track designation has been granted to OBX-115, a TIL cell therapy for the potential treatment of patients with advanced melanoma.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Nikhil Khushalani, MD, discussed a phase 3 study investigating fianlimab plus cemiplimab vs nivolumab and relatlimab for the treatment of patients with advanced melanoma.

During a Case-Based Roundtable® event, Michael A. Postow, MD, reviewed the use of nivolumab plus relatlimab for patients with advanced melanoma in the first article of a 2-part series.